Ester Del Signore

907 total citations
46 papers, 589 citations indexed

About

Ester Del Signore is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ester Del Signore has authored 46 papers receiving a total of 589 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Ester Del Signore's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ester Del Signore is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ester Del Signore collaborates with scholars based in Italy, United States and Lebanon. Ester Del Signore's co-authors include Filippo de Marinis, Antonio Passaro, Gianluca Spitaleri, Bruno Gori, Ilaria Attili, Alberto Fulvi, Serena Ricciardi, Chiara D’Antonio, Maria Rita Migliorino and Chiara Catania and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Molecules.

In The Last Decade

Ester Del Signore

44 papers receiving 583 citations

Peers

Countries citing papers authored by Ester Del Signore

Since Specialization

Citations

This map shows the geographic impact of Ester Del Signore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ester Del Signore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ester Del Signore more than expected).

Fields of papers citing papers by Ester Del Signore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ester Del Signore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ester Del Signore. The network helps show where Ester Del Signore may publish in the future.

Co-authorship network of co-authors of Ester Del Signore

This figure shows the co-authorship network connecting the top 25 collaborators of Ester Del Signore. A scholar is included among the top collaborators of Ester Del Signore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ester Del Signore. Ester Del Signore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer 2025 ·Genes ·Panagiotis Angelopoulos, Antonio Passaro, Ilaria Attili, Pamela Trillo Aliaga, Carla Corvaja, Gianluca Spitaleri, (unknown), Ester Del Signore, Giuseppe Curigliano, Filippo de Marinis	1
2	Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study 2025 ·Clinical Lung Cancer ·Ilaria Attili, (unknown), Luca Bertolaccini, Carla Corvaja, Davide Vacirca, M. Lombardi, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro, Juliana Guarize, Elena Guerini‐Rocco, Nicola Fusco, Lorenzo Spaggiari, Filippo de Marinis	0
3	Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions 2025 ·Cancer Treatment Reviews ·Ilaria Attili, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis	1
4	The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics 2024 ·Genes ·Pamela Trillo Aliaga, Ester Del Signore, (unknown), Gianluca Spitaleri, (unknown), Ilaria Attili, Carla Corvaja, (unknown), Antonio Passaro, Filippo de Marinis	1
5	Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials 2024 ·Cancers ·Ilaria Attili, (unknown), Gianluca Spitaleri, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, (unknown), (unknown), Antonio Passaro, Filippo de Marinis	4
6	Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs” 2024 ·Cancers ·Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, (unknown), (unknown), Antonio Passaro, Filippo de Marinis	2
7	Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis 2024 ·Journal of Clinical Medicine ·Ilaria Attili, (unknown), Davide Vacirca, (unknown), Alessandra Rappa, Alberto Ranghiero, M. Lombardi, Carla Corvaja, (unknown), (unknown), Pamela Trillo Aliaga, Gianluca Spitaleri, Ester Del Signore, Juliana Guarize, Lorenzo Spaggiari, Elena Guerini‐Rocco, Nicola Fusco, Filippo de Marinis, Antonio Passaro	5
8	Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings 2024 ·Cancers ·Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro, Filippo de Marinis	7
9	Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario 2024 ·Current Oncology ·(unknown), Ilaria Attili, Carla Corvaja, (unknown), (unknown), Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis	7
10	Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach 2024 ·Critical Reviews in Oncology/Hematology ·Giovanni Luca Ceresoli, Giulio Rossi, Francesco Agustoni, Lucia Bonomi, Paolo Borghetti, Alessandra Bulotta, (unknown), Giulio Cerea, Francesca Colonese, Ester Del Signore, Giovanna Finocchiaro, Letizia Gianoncelli, Salvatore Grisanti, (unknown), Fabio Pagni, Claudia Proto, Erika Rijavec, (unknown), Stefano Arcangeli, Andrea Riccardo Filippi	1
11	MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target 2023 ·Cancers ·Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, (unknown), Antonio Passaro, Filippo de Marinis	12
12	New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations 2023 ·Cancers ·Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Ester Del Signore, Pamela Trillo Aliaga, Antonio Passaro, Filippo de Marinis	27
13	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50% 2022 ·Frontiers in Oncology ·Ilaria Attili, Carmine Valenza, (unknown), Gabriele Antonarelli, Pamela Trillo Aliaga, Ester Del Signore, Chiara Catania, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis	6
14	1533P Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): Results from the interim analysis of MAURIS trial 2022 ·Annals of Oncology ·Emilio Bria, Marina Chiara Garassino, Ester Del Signore, (unknown), (unknown), (unknown), (unknown), Andrea Ardizzoni	1
15	The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature 2021 ·Clinical Lung Cancer ·Chiara Catania, (unknown), Gianluca Spitaleri, Ester Del Signore, Nathan A. Pennell	12
16	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis 2019 ·Anticancer Research ·Letizia Gianoncelli, Gianluca Spitaleri, Antonio Passaro, Davide Radice, Caterina Fumagalli, Ester Del Signore, Valeria Stati, Chiara Catania, Elena Guerini‐Rocco, Massimo Barberis, Filippo de Marinis	18
17	Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7? 2016 ·Journal of Thoracic Disease ·Antonio Passaro, (unknown), Gianluca Spitaleri, Chiara Catania, Cristina Noberasco, Ester Del Signore, Filippo de Marinis	5
18	Management of Nonhematologic Toxicities Associated With Different EGFR-TKIs in Advanced NSCLC: A Comparison Analysis 2014 ·Clinical Lung Cancer ·Antonio Passaro, Massimo Di Maïo, Ester Del Signore, Bruno Gori, Filippo de Marinis	23
19	Capecitabine in elderly patients with metastatic breast cancer 2012 ·IRIS Research product catalog (Sapienza University of Rome) ·Rita De Sanctis, Silvia Quadrini, (unknown), Ester Del Signore, (unknown), (unknown), Bruno Gori, Vincenzo Bianco, (unknown), Marisa Di Seri, Flavia Longo, (unknown), (unknown)	3
20	Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 2010 ·Supportive Care in Cancer ·Flavia Longo, Giovanni Mansueto, (unknown), Rita De Sanctis, Silvia Quadrini, Roberta Grande, Bruno Gori, Amelia Altavilla, (unknown), Ester Del Signore, (unknown), Cristina De Luca, (unknown), Enrico Cortesi, Teresa Gamucci, Marisa Di Seri	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact